Evaluation of the nonparametric estimation method in nonmem VI: Application to real data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 4, 2009, Pages 297-315

  Baverel, Paul G ^a   Savic, Radojka M ^a   Wilkins, Justin J ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bias; Imprecision; Nonparametric estimation method; Numerical predictive check (NPC); Simulation properties

Indexed keywords

CLADRIBINE; DESMOPRESSIN; DIGOXIN; DOCETAXEL; GEFITINIB; GLIBENCLAMIDE; LEVODOPA; LEVOSIMENDAN; MELAGATRAN; MOXONIDINE; PEFLOXACIN; PRAZOSIN; PYRAZINAMIDE; TOBRAMYCIN; VORICONAZOLE;

ALGORITHM; ARTICLE; BAYES THEOREM; DATA ANALYSIS; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL PARAMETERS; MAXIMUM LIKELIHOOD METHOD; METHODOLOGY; NONPARAMETRIC ESTIMATION METHOD; NUMERICAL PREDICTIVE CHECK; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

COMPUTER SIMULATION; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; PHARMACOKINETICS; SOFTWARE; SOFTWARE VALIDATION; STATISTICS, NONPARAMETRIC;

EID: 69049111673     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9122-z     Document Type: Article

References (42)

1. R Jelliffe A Schumitzky M Van Guilder 2000 Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods Ther Drug Monit 22 3 354 365 10.1097/00007691-200006000-00019
2. A Mallet F Mentre JL Steimer F Lokiec 1988 Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine J Pharmacokinet Biopharm 16 3 311 327 10.1007/BF01062140
3. Leary RH, Jelliffe R, Schumitzky A, Van Guilder M (2002) A unified parametric/nonparametric approach to PK/PD population modeling, Abstr 302, p 11. www.page-meeting.org/?abstract=302
4. A Bustad D Terziivanov R Leary, et al. 2006 Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies Clin Pharmacokinet 45 4 365 383 10.2165/00003088-200645040-00003
5. Leary RH, Jelliffe R, Schumitzky A, Van Guilder M (2001) An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. 14th institute of electrical and electronics engineers symposium on computer-based medical systems, IEEE, Bethesda, MD, pp 389-394
6. A Mallet 1986 A maximum likelihood estimation method for random coefficient regression models Biometrika 3 645 656 10.1093/biomet/73.3.645
7. RM Savic MC Kjellsson MO Karlsson 2009 Evaluation of the nonparametric estimation method in NONMEM VI Eur J Pharm Sci 37 1 27 35 10.1016/j.ejps.2008. 12.014
8. Wilkins JJ, Karlsson MO, Jonsson EN (2006) Patterns and power for the visual predictive check, Abstr 1029, p 15. www.page-meeting.org/?abstract=1029
9. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming Comput Method Program Biomed 75 2 85 94 10.1016/j.cmpb.2003.11.003
10. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 4 503 512 10.1007/BF01060893
11. R Development Core Team (2006) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org
12. Hastie T GAM (2006) Generalized additive models. R package version 0.98
13. AC Hooker CE Staatz MO Karlsson 2007 Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method Pharm Res 24 12 2187 2197 10.1007/s11095-007-9361-x
14. C Dartois A Lemenuel-Diot C Laveille, et al. 2007 Evaluation of uncertainty parameters estimated by different population PK software and methods J Pharmacokinet Pharmacodyn 34 3 289 311 10.1007/s10928-006-9046-9
15. DB White CA Walawander Y Tung TH Grasela 1991 An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis J Pharmacokinet Biopharm 19 1 87 112
16. Garrido MJ, Cendrós J, Ramis J et al (2008) Simultaneous population pharmacodynamic modelling of the growth hormone and insulin-like growth factor-I effects after deep subcutaneous administration of Lanreotide Autogel® in acromegalic patients. Application of nonparametric estimation method in NONMEM, Abstr 1366, p 17. www.page-meeting.org/?abstract=1366
17. B Hamren H Ericsson O Samuelsson MO Karlsson 2008 Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function - evidence of interconversion Br J Clin Pharmacol 65 6 855 863 10.1111/j.1365-2125.2008.03110.x
18. Savic RM, Wilkins JJ, Karlsson MO (2006) (Un)informativeness of empirical bayes estimate-based diagnostics. AAPS J Am Assoc Pharm Sci
19. J Antic CM Laffont D Chafaï D Concordet 2009 Comparison of nonparametric methods in nonlinear mixed effects models Comput Stat Data Anal 53 642 656 10.1016/j.csda.2008.08.021
20. Savic RM, Karlsson MO (2007) Evaluation of extended grid methods for estimation using nonparametric distribution. AAPS J 9(S2): Abstr W4536
21. Savic RM, Baverel PG, Karlsson MO (2008) A novel bootstrap method for obtaining uncertainty measurement around the nonparametric distribution, Abstr 1390, p 17. www.page-meeting.org/?abstract=1390
22. S Lindemalm RM Savic MO Karlsson, et al. 2005 Application of population pharmacokinetics to cladribine BMC Pharmacol 5 1 4 10.1186/1471-2210-5-4
23. R Bruno MC Iliadis B Lacarelle, et al. 1992 Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients J Pharmacokinet Biopharm 20 6 653 669 10.1007/BF01064424
24. T Rydberg A Jonsson MO Karlsson A Melander 1997 Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics Br J Clin Pharmacol 43 4 373 381 10.1111/j.1365-2125.1997.00571.x
25. RM Savic DM Jonker T Kerbusch MO Karlsson 2007 Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies J Pharmacokinet Pharmacodyn 34 5 711 726 10.1007/s10928-007-9066-0
26. O Osterberg RM Savic MO Karlsson, et al. 2006 Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults J Clin Pharmacol 46 10 1204 1211 10.1177/0091270006291838
27. EN Jonsson S Antila L McFadyen L Lehtonen MO Karlsson 2003 Population pharmacokinetics of levosimendan in patients with congestive heart failure Br J Clin Pharmacol 55 6 544 551 10.1046/j.1365-2125.2003.01778.x
28. PH Zingmark C Edenius MO Karlsson 2004 Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS Br J Clin Pharmacol 58 4 378 389 10.1111/j.1365-2125.2004.02177.x
29. MO Karlsson EN Jonsson CG Wiltse JR Wade 1998 Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients J Pharmacokinet Biopharm 26 2 207 246 10.1023/A:1020561807903
30. G Hempel MO Karlsson DP de Alwis, et al. 1998 Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements Clin Pharmacol Ther 64 6 622 635 10.1016/S0009-9236(98)90053-4
31. J Li MO Karlsson J Brahmer, et al. 2006 CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors J Natl Cancer Inst 98 23 1714 1723
32. Cullberg M, Wåhlander K, Lundström T et al (2006) Ximelagatran in extended secondary prevention of venous thromboembolism: pharmacokinetics, pharmacodynamics and relationships to clinical events. Doctoral thesis of Marie Cullberg from the Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Sciences, Uppsala University, Sweden
33. JJ Wilkins G Langdon H McIlleron, et al. 2006 Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients Eur J Clin Pharmacol 62 9 727 735 10.1007/s00228-006-0141-z
34. MO Karlsson LB Sheiner 1993 The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 21 6 735 750 10.1007/BF01113502
35. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm 20 5 511 528 10.1007/BF01061469
36. L Aarons S Vozeh M Wenk P Weiss F Follath 1989 Population pharmacokinetics of tobramycin Br J Clin Pharmacol 28 3 305 314
37. Lindemalm S, Liliemark J, Gruber A et al (2001) Antiproliferative activity in relation to levels of phosphorylated 2-chloro-2′- deoxyadenosine and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine and levels of activating enzymes in leukaemia cells. Doctoral thesis of Synnöve Lindemalm from the Department of Medicine Division of Clinical Pharmacology Karolinska Institute and Hospital Stockholm, Sweden
38. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 24 4713 4721 10.1200/JCO.2002.02.140
39. IF Troconiz TH Naukkarinen HM Ruottinen, et al. 1998 Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone Clin Pharmacol Ther 64 1 106 116 10.1016/S0009-9236(98) 90028-5
40. L Brynne JL McNay HG Schaefer, et al. 2001 Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure Br J Clin Pharmacol 51 1 35 43 10.1046/j.1365-2125.2001.01320.x
41. Hamren B, Björk E, Karlsson MO (2006) Mechanism-based pharmacokinetic and pharmacodynamic modeling of tesaglitazar in type 2 diabetes patients, Abstr 961, p 15. www.page-meeting.org/?abstract=961
42. B Hornestam M Jerling MO Karlsson P Held 2003 Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the digitalis in acute atrial fibrillation trial Eur J Clin Pharmacol 58 11 747 755